MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions.
The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. The transaction is expected to close by the end of the second quarter of 2026.
Protein A chromatography plays a critical role in the purification of monoclonal antibodies and therapeutic proteins, which are used for treating cancers, autoimmune diseases, and infectious conditions. This specialized purification process is key to achieving high purity and enhanced drug safety, while also improving manufacturing speed and reliability. Ultimately, that means helping patients gain faster access to critical therapies.
Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The company is known for its high-performing Amsphere™ A3 and Amsphere™ A+ Protein A resins, which offer superior purification performance and process robustness for a wide range of monoclonal antibodies.
